Results 101 to 110 of about 93,929 (247)
Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. [PDF]
, 2015 Tyrosine kinase inhibitors (TKIs) including axitinib have been introduced in the treatment of renal cell carcinoma (RCC) because of their anti-angiogenic properties.
Amantini, C +6 more
core +1 more source
International Journal of Cancer, EarlyView.Although lenvatinib is the current first‐line therapy for radioiodine‐refractory differentiated thyroid carcinoma, its use is limited by severe side effects and reduced sensitivity. Here, the authors assessed the potential of sensitizing differentiated thyroid carcinoma tumor cells with limited lenvatinib responsiveness through the administration of ...
Celina Ablinger +13 more
wiley +1 more source
Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma [PDF]
, 2017 PURPOSE: To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational, randomized, phase III trial.
Bruix Tudó, Jordi +13 more
core +1 more source
The Endothelial CXCR Family in Vascular Health and Disease
iNew Medicine, EarlyView.ABSTRACT Endothelial cells (ECs) form the dynamic interface between blood and tissue, serving as key regulators of vascular homeostasis, inflammation, and repair. Among the molecular systems governing endothelial behavior, the C‐X‐C motif chemokine receptor (CXCR) family—originally characterized in immunology for its roles in leukocyte trafficking and ...
Zhiming Wu +4 more
wiley +1 more source
Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF [PDF]
, 2010 Background Cumulative light exposure is significantly associated with progression of age-related macular degeneration (AMD). Inhibition of vascular endothelial growth factor is the main target of current antiangiogenic treatment strategies in AMD ...
Alge, C. S. +7 more
core +3 more sources
Molecular Carcinogenesis, EarlyView.ABSTRACT Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancer. Despite recent advances in treating BRAFV600E‐driven ATC, therapy resistance remains a significant challenge, often resulting in disease progression and death.
Shawn Noronha +26 more
wiley +1 more source
Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma
Cellular Physiology and Biochemistry, 2017 Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and prognosis remains unsatisfactory since the disease is often diagnosed at the advanced stages.
Ting Sun, Hongchun Liu, Liang Ming
doaj +1 more source
Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression [PDF]
, 2017 Gastrointestinal cancer is a group of tumors that affect multiple sites of the digestive system, including the stomach, liver, colon and pancreas. These cancers are very aggressive and rapidly metastasize, thus identifying effective targets is crucial ...
Bacigalupo, Maria Lorena +2 more
core +1 more source
The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one [PDF]
, 2018 In renal cancer emerging treatment options are becoming available and there is a strong need to combine therapies to reformulate and adjourn clinical practice.
Botticelli, A. +4 more
core +1 more source
Portal Hypertension &Cirrhosis, EarlyView.Thrombocytopenia is common in hepatocellular carcinoma and may increase bleeding risk during antiangiogenic therapy, yet the clinically relevant platelet threshold remains uncertain. We found that a baseline platelet count < 50 × 109/L was associated with bleeding; patients below this cutoff had a substantially higher bleeding rate than those with ...
Jun Tie +8 more
wiley +1 more source